Nicolas Ortonne, et al.. MYD88 somatic mutation is a diagnostic criterion in primary cutaneous large B-cell lymphoma.
. While the latter category displays an aggressive behaviour requiring a combination of rituximab and polychemotherapy (Grange et al., 2014) , first line therapy of the two former categories which have an indolent course consists in local therapy especially in patients with solitary or localized lesions (Senff et al., 2008) . However, patients with PCFCL presenting on the leg have a worse prognosis and may require a systemic therapy (Senff et al., 2007) . Moreover, differential diagnosis between PCDLBCL-LT and PCFCL may be challenging especially when PCFCL exhibit large cell morphology. Hierarchical determination of CD10, BCL6 and MUM1 expression according to the Hans' algorithm (Hans et al., 2004) is not a reliable tool for cutaneous B-cell lymphoma diagnosis as CD10 expression may be lost in PCFCL and BCL6 may be expressed as frequently in PCDLBCL-LT than in PCFCL (Dewar et al., 2015) . Moreover, such algorithm does not include BCL2 immunostaining which is a major diagnostic and prognostic factor for primary cutaneous large B-cell lymphoma (PCLBCL) (Grange et al., 2004) .
MYD88, a gene encoding for an adaptor protein of both Toll-like receptors and
Interleukin-1 receptors was recently shown to exhibit driver oncogenic mutations in nodal activated B-cell diffuse large cell lymphoma (ABC DLBCL) resulting in NF-kB signaling pathway activation (Ngo et al., 2010) . We previously reported the high prevalence of MYD88 L265P mutation in above 60% of the 58 PCDLBCL-LT studied
cases using a robust and highly sensitive allele specific PCR technique (Pham-Ledard et al., 2014) , while others described a lower rate at 40% in ten patients (Koens et al., 2014) . Whether such assessment could discriminate PCFCL with large cell morphology from PCDLBCL-LT has not been evaluated. Indeed, only 3 PCFCL with large cell morphology cases were included in our initial study and exhibited a wild type MYD88 status using a Sanger sequencing technique (Pham-Ledard et al., 2012) . Table 1 . The gender-ratio (male/female) was 2.5 for PCFCL, large cell and 0.4 for PCDLBCL-LT. Patients with PCDLBCL-LT were older than patients with PCFCL, large cell. Localization on the lower limb was found in 80% of PCDLBCL-LT and 9.5% of PCFCL cases. While BCL2 and MUM1 expression by more than 50% of tumor cells was a recurrent feature of PCLBCL-LT (100%), PCFCL, large cell type cases were typically considered negative for BCL2 (81%) and MUM1 (100%) when using a cut-off criteria of 50% for BCL2 and 80% for MUM1. However, such phenotypic criteria are not always reached and a partial overlap of individual marker expression may be observed between PCFCL with a diffuse growth pattern M A N U S C R I P T
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presenting on the leg and PCDLBCL-LT (Kempf et al., 2014) . Indeed, MUM1 expression was observed in less than 80% of tumor cells but above 50% in five cases of PCLBCL-LT (20%). In addition, partial MUM1 expression ranging from 10% to 40% of tumor cells was observed in seven PCFCL, large cell type cases (33%), as reported by others (Hoefnagel et al., 2006) . Finally, four PCFCL, large cell type samples (19%) exhibited a strong BCL2 immunostaining in more than 50% of tumor cells, only one of them occurring at the leg site. These four cases were however all MUM1 negative. A MYD88 L265P mutation was detected in 19 out of 25 (76%) PCDLBCL-LT cases with a slight difference between those developing at the leg site (16 out of 20, 80%) and those developing at other sites (3 out of 5, 60%) (Table 1) .
Interestingly, the MYD88 L265P mutation was never detected in the 21 PCFCL cases.
Specificity and Positive Predictive Value for MYD88 status were determined both at 100% while Negative Predictive Value was at 78 %.
This study not only confirms the original and high prevalence of the MYD88 L265P mutation in PCLBCL-LT but also underscores that such determination may be relevant to differentiate this entity from PCFCL cases with large cell morphology. According to prognosis difference between the two diseases and international guidelines (Senff et al., 2007; Senff et al., 2008) , the two groups of patients were treated differently hampering evaluation of the impact of MYD88 status on prognosis.
We already reported that MYD88 L265P mutation is an independent bad prognosis factor in patients with PCLBCL-LT whatever the treatment they have received (Pham-Ledard et al., 2014) . Such feature was also recently reported in patients with nodal or systemic DLBCL carrying the MYD88 L265P mutation (Rovira et al., 2016) . Despite improvement in the prognosis of patients with PCLBCL-LT since the introduction of rituximab in front-line therapy in association with polychemotherapy (Grange et al., 
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A C C E P T E D ACCEPTED MANUSCRIPT 2014), a significant proportion of these patients will relapse and often disseminate to extra-cutaneous sites. Therefore determination of MYD88 status along with other mutations could also be relevant to identify patients which could respond to specific therapy targeting either the BCR, JAK/STAT or NF-kB signaling pathways (Wilson et al., 2015) . Altogether, the present study supports that MYD88 status is a necessary biomarker in patients with primary cutaneous large B-cell lymphomas both for diagnosis, prognosis and management purpose. 
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